Carlos Bea

Dr. Carlos Bea

Hospital Clínico Universitario de Valencia, Valencia, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2014 in Journal of Anatomy
Verified
Journal Article
Closed access
PDF file
Víctor Marcos-GarcésVíctor Marcos-Garcés
Víctor Marcos-Garcés
PAP. Molina Aguilar
P. Molina Aguilar
CBCarlos Bea
Carlos Bea
VGVíctor Garcia-Bustos
Víctor Garcia-Bustos
JSJ. Benavent Seguí
J. Benavent Seguí
Amparo Ruiz-SauríAmparo Ruiz-Saurí
Amparo Ruiz-Saurí

Verified
Journal Article
Open access
PDF file
CBCarlos Bea
Carlos Bea
SVSara Vela-Bernal
Sara Vela-Bernal
SGSergio García-Blas
Sergio García-Blas
JPJose-Angel Perez-Rivera
Jose-Angel Perez-Rivera
PDPablo Diez-Villanueva
Pablo Diez-Villanueva
Clara BonanadClara Bonanad
Clara Bonanad
The specific management of infective endocarditis (IE) in elderly patients is not specifically addressed in recent guidelines despite its increasing incidence and high mortality in this population. The term “elderly” corresponds to different ages in the literature, but it is defined by considerable comorbidity and heterogeneity. Cancer incidence, specifically colorectal cancer, is increased in older patients with IE and impacts its outcome. Diagnosis of IE in elderly patients is challenging due to the atypical presentation of the disease and the lower performance of imaging studies. Enterococcal etiology is more frequent than in younger patients. Antibiotic treatment should prioritize diminishing adverse effects and drug interactions while maintaining the best efficacy, as surgical treatment is less commonly performed in this population due to the high surgical risk. The global assessment of elderly patients with IE, with particular attention to frailty and geriatric profiles, should be performed by multidisciplinary teams to improve disease management in this population.

21 January 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
JCJose Miguel Calderon
Jose Miguel Calderon
FMFernando Martinez
Fernando Martinez
JDJavier Diaz
Javier Diaz
AFAntonio Fernandez
Antonio Fernandez
ISInmaculada Sauri
Inmaculada Sauri
MFMaria Jose Forner
Maria Jose Forner
Aims: To assess the impact of anticoagulant treatment on risk for stroke and all-cause mortality of patients with atrial fibrillation using real-world data (RWD). Methods: Patients with prevalent or incident atrial fibrillation were selected throughout a study period of 5 years. Stroke, transitory ischemic attack, hemorrhagic stroke, and all-cause mortality were identified in the claims of the electronic health records (EHRs). Subjects were classified according to the anticoagulant treatment in four groups: untreated, vitamin K antagonists (VKAs), New Oral Anticoagulants (NOACs), and antiplatelet (AP). Risk of events and protection with anticoagulant therapy were calculated by Cox proportional hazard models adjusted by potential confounders. Results: From a total population of 3,799,884 patients older than 18,123,227 patients with incident or prevalent atrial fibrillation (AF) were identified (mean age 75.2 ± 11.5 years old; 51.9% women). In a follow-up average of 3.2 years, 17,113 patients suffered from an ischemic stroke and transitory ischemic attack (TIA), 780 hemorrhagic stroke, and 42,558 all-cause death (incidence of 46, 8, 2, and 120 per 1,000 patients/year, respectively). Among CHA2DS2, VASc Score equal or >2, 11.7% of patients did not receive any anticoagulant therapy, and a large proportion of patients, 47%, shifted from one treatment to another. Although all kinds of anticoagulant treatments were significantly protective against the events and mortality, NOAC treatment offered significantly better protection compared to the other groups. Conclusion: In the real world, the use of anticoagulant treatments is far from guidelines recommendations and is characterized by variability in their use. NOACs offered better protection compared with VKAs.

15 September 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
CBCarlos Bea
Carlos Bea
ABAndreu Belmonte-Domingo
Andreu Belmonte-Domingo
CPCarolina Pinto Pla
Carolina Pinto Pla
AFAna Ferrer
Ana Ferrer
SVSara Vela-Bernal
Sara Vela-Bernal
MOMaría Rosa Oltra-Sempere
María Rosa Oltra-Sempere
Background: Clostridioides difficile infection (CDI) is the leading cause of nosocomial diarrhea. Current diagnostic tools have difficulty distinguishing between colonization and active infection. This study evaluated the utility of fecal metabolomics in diagnosing CDI in hospitalized patients with acute diarrhea. Methods: We conducted a prospective observational study involving hospitalized adults with new-onset diarrhea during admission. Participants were stratified into groups based on clinical and microbiological findings: controls, C. difficile colonized and C. difficile infected. Fecal samples were analyzed using UPLC-MS/MS and GC-MS to quantify selected short-chain fatty acids, amino acids, and bile acids. Multivariate and univariate statistical analyses included PLS-DA, sPLSDA, and tests with FDR correction. Results: Infected patients exhibited significantly higher concentrations of SCFAs and notable alterations in bile acid profiles. Key discriminative metabolites included isovalerate, propionate, isobutyrate and alpha-aminobutyric acid. ROC curve analyses showed strong diagnostic performance for these markers, with AUC values exceeding 0.85. Conclusions: Fecal metabolomic profiling could effectively differentiate between colonization and infection in CDI among hospitalized patients with diarrhea. These results highlight the potential of metabolomic signatures to enhance the diagnostic precision for CDI.

Verified
Journal Article
Open access
PDF file
CLCristina Lopez
Cristina Lopez
JSJose Luis Holgado Sanchez
Jose Luis Holgado Sanchez
AFAntonio Fernandez-Gimenez
Antonio Fernandez-Gimenez
IFInma Sauri Ferrer
Inma Sauri Ferrer
RURuth Usó-Talamantes
Ruth Usó-Talamantes
JRJosep Redon
Josep Redon
Aims: This study assessed the impact of acute hemoglobin (Hb) falls in heart failure (HF) patients. Methods: HF patients with repeated Hb values over time were included. Falls in Hb greater than 30% were considered to represent an acute episode of anemia and the risk of hospitalization and all-cause mortality after the first episode was assessed. Results: In total, 45,437 HF patients (54.9% female, mean age 74.3 years) during a follow-up average of 2.9 years were analyzed. A total of 2892 (6.4%) patients had one episode of Hb falls, 139 (0.3%) had more than one episode, and 342 (0.8%) had concomitant acute kidney injury (AKI). Acute heart failure occurred in 4673 (10.3%) patients, representing 3.6/100 HF patients/year. The risk of hospitalization increased with one episode (Hazard Ratio = 1.30, 95% confidence interval (CI) 1.19–1.43), two or more episodes (HR = 1.59, 95% CI 1.14–2.23, and concurrent AKI (HR = 1.61, 95% CI 1.27–2.03). A total of 10,490 patients have died, representing 8.1/100 HF patients/year. The risk of mortality was HR = 2.20 (95% CI 2.06–2.35) for one episode, HR = 3.14 (95% CI 2.48–3.97) for two or more episodes, and HR = 3.20 (95% CI 2.73–3.75) with AKI. In the two or more episodes and AKI groups, Hb levels at the baseline were significantly lower (10.2–11.4 g/dL) than in the no episodes group (12.8 g/dL), and a higher and significant mortality in these subgroups was observed. Conclusions: Hb falls in heart failure patients identified those with a worse prognosis requiring a more careful evaluation and follow-up.

1 April 2021 in Journal Of Hypertension
Verified
Journal Article
Closed access
ISInmaculada Sauri
Inmaculada Sauri
RURuth Uso
Ruth Uso
JTJose Luis Trillo
Jose Luis Trillo
AFAntonio Fernandez
Antonio Fernandez
JHJose Luis Holgado
Jose Luis Holgado
JRJosep Redon
Josep Redon
Objective: To assess the impact of hypertension in the risk of cardiovascular events and mortality in a population of diabetic patients from a Mediterranean population based in Real World Evidence. Design and method: The sample was recruited from beneficiaries of the Valencian Health Agency's health care system, with a population of 3799884 people older than 25 years in 2012. The observational study was undertaken as part of routine clinical practice from January 2012 to December 2016. Diabetes was defined as a non-fasting glucose higher or equal to 200 mg/dl, a recorded physician diagnosis, medication use or an HbA1c higher or equal to 6.5%. Hypertension was defined by a recorded physician diagnosis or antihypertensive medication use. Estimated glomerular filtration rate (eGFR) was calculated from calibrated creatinine, age and sex using the CKD-EPI and CKD was defined when eGFR < 60 ml/min/1.73m2. Vital status was determined by matching records and death certificates from the Spanish National Death Index. Results: Among the total population of 3799884, DM was present in 510922 (13%) patients (12% in women and 15% in men), Average of HbA1c was 6.9% + 1.4%. Hypertension was recorded in 387590 (75%) with a rate of BP < 140/90 mmHg of 45% and CKD in 125441 (24%). The incidence rates for DM, with and without diagnostic of HTN, of acute myocardial infarction, heart failure and stroke, as well all-cause mortality by age and sex rates are in the figure, in which the times of increment of risk due to the presence of HTN is presented. Conclusions: Presence of HTN in patients of diabetes largely increases the risk of MI, stroke, HF and all-cause mortality. The impact even it is higher in more younger patients, it still until the last decade of life.